J Korean Endocr Soc.  2006 Oct;21(5):352-363. 10.3803/jkes.2006.21.5.352.

NF-kappaB Pathway in Metabolic/endocrine Diseases

• Lee MS
• Kim KA

• KMID: 1511983
• DOI: http://doi.org/10.3803/jkes.2006.21.5.352

Abstract

No abstract available.

MeSH Terms

NF-kappa B*
NF-kappa B

Figure

• 

  Fig. 1 Activation of two NF-κB signaling pathways. Activation of NF-κB by immune stimuli involves canonical and noncanonical pathways, which are based on degradation of IκB or processing of p100, respectively. The canonical pathway is stimulated by diverse cellular stimuli, such as antigens and cytokines, and is dependent on the trimeric IKK complex. The noncanonical pathway responds to a subset of TNF family members, including BAFF and CD40L, and requires IKKα but not IKKγ or IKKβ. BAFF; B cell activating factor.

• 

  Fig. 2 Proposed model of metabolic and inflammatory signaling and sensing pathways in adipocytes, macrophages and hepatocytes. Adipocytes secrete factors that attract monocytes and lead to differentiation of monocytes into resident macrophages. Together, adipocytes and macrophages interact, increasing circulating proinflammatory cytokines, promoting a chronic, systemic inflammatory response that adversely affects metabolic function and leads to diabetes. Inflammatory pathways can be initiated by extracellular mediators such as cytokines and lipids or by intracellular stresses such as ER stress or excess ROS production by mitochondria. Signals from all of these mediators converge on inflammatory signaling pathways, including IKK. Key initiating events in the liver are 1) hepatic activation of serine/threonine kinases (IKK), which presumably caused insulin resistance at the IRS-1/2 level, and 2) the activation of the IKK/IκBα/NF-κB pathway (via PKC, ROS, or other mechanisms), leading to expression and secretion of inflammatory cytokines (TNFα, IL-1, IL-6, and MCP-1). ICAM, intercellular adhesion molecule; IL-6, interleukin-6; IR, insulin receptor; IRS, insulin receptor substrate; MCP-1, monocyte chemoattractant protein-1; M-CSF, macrophage colony-stimulating factor; MIF, macrophage migration inhibitory factor MIP, macrophage inflammatory protein; PAI-1, plasminogen activator inhibitor-1; TNF-α, tumor necrosis factor-α.

• 

  Fig. 3 Schematic representation of atherogenesis. Indicated are the different cell types involved and the different steps in the atherosclerotic process potentially affected by NF-B activation. (1)Initiation of atherosclerosis is characterized by the formation of modified LDL (mLDL), followed by the subsequent activation of endothelial cells and secretion of chemokines. On migration through the endothelial layer, the monocytes differentiate into macrophages and scavenge the modified LDL from the vessel wall, resulting in (2) foam cell formation. Persistent hypercholesterolemia leads to intracellular accumulation of cholesteryl esters and eventually apoptosis and release of proinflammatory oxidized lipid derivatives into the plaque, further exacerbating the (3)inflammatory responses. (4), (5) Later stages involve the formation of a fibrotic cap through proliferation and migration of smooth muscle cells and cell death resulting in a necrotic core. SR indicates scavenger receptor. Modified from reference[88].

Reference

1. Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein NF-kappa B by a posttranslational mechanism. Cell. 1988. 47:921–928.

2. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IkB kinase that activates the transcriptional factor NF-kB. Nature. 1997. 388:548–554.

3. Lin A, Karin M. NF-kB in cancer: a marked target. Semin Cancer Biol. 2003. 13:107–114.

4. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell. 1996. 86:973 –983.

5. Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997. 388:394–397.

6. Beulter B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature. 2004. 430:257–263.

7. Beg AA, Sha WC, Bronson RI, Ghosh S, Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kB. Nature. 1995. 376:167–170.

8. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-kB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998. 281:1680–1683.

9. Wang CY, Mayo MW, Baldwin AS. TNF- and cancer-therapy-induced apoptosis: potentiation by inhibition of NF-kB. Science. 1996. 274:784–787.

10. Beg AA, Baltimore D. An essential role for NF-kB in preventing TNF-induced cell death. Science. 1996. 274:782–784.

11. Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science. 1999. 284:321–325.

12. Park JM, Greten FR, Li ZW, Karin M. Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science. 2002. 297:2048–2051.

13. Kim HS, Lee MS. Essential role of STAT1 in caspase-independent cell death of activated macrophages through p38 MAPK/STAT1/ROS pathway. Mol Cell Biol. 2005. 25:6821–6833.

14. Suk K, Chang I, Kim YH, Kim S, Kim JY, Kim H, Lee MS. Interferon gamma (INFgamma) and tumor necrosis alpha synergism in ME-180 cervical cancer cell apoptosis and necrosis. INFgamma inhibits cytoprotective NF-kappa B through STAT1/IRF-1 pathway. J Biol Chem. 2001. 276:13153–13159.

15. Suk K, Kim YH, Chang I, Kim JY, Choi YH, Lee KY, Lee MS. IFNalpha sensitizes ME-180 human cervical cancer cells to TNFalpha-induced apoptosis by inhibiting cytoprotective NF-kappaB activation. FEBS Lett. 2001. 495:66–70.

16. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol. 1998. 161:2833–2840.

17. Thomas WD, Hersey P. TNF-related apoptosis -inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol. 1998. 161:2195–2200.

18. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JCL, Lynch DH. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999. 5:157–163.

19. Deng Y, Lin Y, Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/BIABLO. Genes Dev. 2002. 16:33–45.

20. Kandasamy K, Srinivasula SM, Alnemri ES, Thompson CB, Korsmeyer SJ, Bryant JL, Srivastava RK. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis -inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. Cancer Res. 2003. 63:1712–1721.

21. Kim JY, Kim YH, Chang I, Kim S, Pak YK, Oh BH, Yagita H, Jung YK, Oh YJ, Lee MS. Resistance of mitochondrial DNA-deficient cells to TRAIL: role of Bax in TRAIL-induced apoptosis. Oncogene. 2002. 21:3139 –3148.

22. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997. 277:818–821.

23. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science. 1997. 276:111–113.

24. Hu WH, Johnson H, Shu HB. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kB and JNK activation and apoptosis through distinct pathways. J Biol Chem. 1999. 43:30603 –30610.

25. Schneider P, Thome M, Burns K, Bodmer J, Hofmann K, Kataoka T, Holler N, Tschopp J. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kB. Immunity. 1997. 7:831–836.

26. Kim HS, Chang I, Kim JY, Choi KH, Lee MS. Caspase-mediated p65 cleavage promotes TRAIL-induced apoptosis. Cancer Res. 2005. 65:6111–6119.

27. Greten FR, Eckmann L, Greten TF, Park JM, Li JW, Egan LJ, Kagnoff MF, Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004. 118:285–296.

28. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-induced apoptosis by NF-kB. Science. 1996. 274:787–789.

29. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kB control. P Natl Acad Sci U S A. 1997. 94:10057–10062.

30. Manna SK, Aggarwal BB. Lipopolysaccharide inhibits TNF-induced apoptosis: role of nuclear factor-kB activation and reactive oxygen intermediates. J Immunol. 1999. 162:1510–1518.

31. Schneider A, Martin-Villalba A, Weih F, Vogel J, Wirth T, Schwaninger M. NF-kB is activated and promotes cell death in focal cerebral ischemia. Nat Med. 1999. 5:554–559.

32. Dumont A, Hehner SP, Hofmann TG, Ueffing M, Droge W, Schmitz ML. Hydrogen peroxide-induced apoptosis is CD95-dependent, requires the release of mitochondria-derived reactive oxygen species and the activation of NF-kB. Oncogene. 1999. 18:747–757.

33. Heimberg H, Heremans Y, Jobin C, Leemans R, Cardozo AK, Darville M, Eizirik DL. Inhibition of cytokine-induced NF-kB activation by adenovirus-mediated expression of NF-kB super-repressor prevents beta-cell apoptosis. Diabetes. 2001. 50:2219–2224.

34. Chen G, Hohmer HE, Gasa R, Tran VV, Newgard CB. Selection of insulinoma cell lines with resistance to interleukin-1beta- and gamma-interferon-induced cytotoxicity. Diabetes. 2000. 49:562–570.

35. Giannoukakis N, Rudert WA, Trucco M, Robbins PD. Protection of human islets from the effects of interleukin-1beta by adenoviral gene transfer of an IkappaB repressor. J Biol Chem. 2000. 275:36509–36513.

36. Sekine N, Ishikawa T, Okazaki T, Hayashi M, Wollheim CB, Fujita T. Synergistic activation of NF-kB and inducible isoform of nitric oxidase synthase induction by interferon-gamma and tumor necrosis factor-alpha in INS-1 cells. J Cell Physiol. 2000. 184:46–57.

37. Han X, Sun Y, Scott S, Bleich D. Tissue inhibitor of metalloproteinase-1 prevents cytokine-mediated dysfunction and cytotoxicity in pancreatic islet and beta-cells. Diabetes. 2001. 50:1047–1055.

38. Campbell KJ, Rocha S, Perkins ND. Active repression of antiapoptotic gene expression by RelA(p65) NF-kB. Mol Cell. 2004. 13:853–865.

39. Suk K, Kim S, Kim YH, Kim KA, Chang I, Yagita H, Shong M, Lee MS. IFNgamma/TNFalpha synergism as the final effector in autoimmune diabetes: A key role for STAT1/IRF-1 in pancreatic β-cell death. J Immunol. 2001. 166:4481–4489.

40. Chang I, Kim S, Kim JY, Cho N, Kim YH, Kim H, Lee MK, Kim KW, Lee MS. Nuclear factor kappaB protects pancreatic beta-cells from tumor necrosis factor-alpha-mediated apoptosis. Diabetes. 2003. 52:1169 –1175.

41. McMillan NAJ, Carpick BW, Hollis B, Toone WM, Zamanian-Daryoush M, Williams BRG. Mutational analysis of the double-stranded RNA (dsRNA) binding domain of the dsRNA-activated protein kinase, PKR. J Biol Chem. 1995. 270:2601–2605.

42. Kim S, Millet I, Cho N, Kim E, Han M, Lee MK, Kim KW, Sherwin RS, Lee MS. NF-kappaB inhibits beta-cell death and prevents diabetes of NOD mice. ADA 65th Scientific Meeting. 2005. . 1614-P.

43. Corbett JA, McDaniel ML. Does nitric oxide mediate autoimmune destruction of beta-cells? Possible therapeutic intervention in IDDM. Diabetes. 1992. 41:897 –903.

44. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia. 1996. 39:1005–1029.

45. Kaneto H, Fujii J, Seo HG, Suzuki K, Matsuoka T, Nakamura M, Tatsumi H, Yamasaki Y, Kamada T, Taniguchi N. Apoptotic cell death triggered by nitric oxide in pancreatic beta-cells. Diabetes. 1995. 44:733–738.

46. Irawaty W, Kay TW, Thomas HE. Transmembrane TNF and IFNgamma induce caspase-independent death of primary mouse pancreatic beta cells. Autoimmunity. 2002. 35:369–375.

47. Arnush M, Heitmeier MR, Scarim AL, Marino MH, Manning PT, Corbett JA. IL-1 produced and released endogenously within human islets inhibits beta cell function. J Clin Invest. 1998. 102:516–526.

48. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993. 259:87–91.

49. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes. 1994. 43:1271–1278.

50. Hotamisligil GS. Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes Relat Metab Disord. 2000. 24:suppl 4. S23–S27.

51. Williamson RT. On the treatment of glycosuria and diabetes mellitus with sodium salicylate. BMJ. 1901. 1:760 –762.

52. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 1998. 396:77 –80.

53. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 2001. 293:1673–1677.

54. Boden G. Pathogenesis of type 2 diabetes. Insulin resistance. Endocrinol Metab Clin North Am. 2001. 30:801 –815.

55. Petersen KF, Shulman GI. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am J Cardiol. 2002. 90:11G–18G.

56. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, Goodyear LJ, Kraegen EW, White MF, Shulman GI. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes. 1999. 48:1270–1274.

57. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes. 2002. 51:2005–2011.

58. Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, Shulman GI. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest. 2001. 108:437–446.

59. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest. 2002. 109:1321–1326.

60. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005. 11:183–190.

61. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, Karin M. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med. 2005. 11:191–198.

62. Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, Shoelson SE. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 2004. 119:285–298.

63. Michelsen KS, Doherty TM, Shah PK, Arditi M. TLR signaling: an emerging bridge from innate immunity to atherogenesis. J Immunol. 2004. 173:5901–5907.

64. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest. 1996. 97:1715–1722.

65. Breuss JM, Cejna M, Bergmeister H, Kadl A, Baumgartl G, Steurer S, Xu Z, Koshelnick Y, Lipp J, De Martin R, Losert U, Lammer J, Binder BR. Activation of nuclear factor-kappa B significantly contributes to lumen loss in a rabbit iliac artery balloon angioplasty model. Circulation. 2002. 105:633–638.

66. Ivandic B, Castellani LW, Wang XP, Qiao JH, Mehrabian M, Navab M, Fogelman AM, Grass DS, Swanson ME, de Beer MC, de Beer F, Lusis AJ. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler Thromb Vasc Biol. 1999. 19:1284–1290.

67. Zhao L, Funk CD. Lipoxygenase pathways in atherogenesis. Trends Cardiovasc Med. 2004. 14:191–195.

68. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci U S A. 1995. 92:8264 –8268.

69. Rajavashisth T, Qiao JH, Tripathi S, Tripathi J, Mishra N, Hua M, Wang XP, Loussararian A, Clinton S, Libby P, Lusis A. Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 1998. 101:2702–2710.

70. Bond M, Fabunmi RP, Baker AH, Newby AC. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett. 1998. 435:29–34.

71. Luttun A, Lutgens E, Manderveld A, Maris K, Collen D, Carmeliet P, Moons L. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation. 2004. 109:1408–1414.

72. Galis ZS, Johnson C, Godin D, Magid R, Shipley JM, Senior RM, Ivan E. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res. 2002. 91:852–859.

73. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, Asano M, Moriwaki H, Seishima M. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2003. 23:656–660.

74. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA. Possible new role for NF-kappaB in the resolution of inflammation. Nat Med. 2001. 7:1291–1297.

75. Xu LG, Wu M, Hu J, Zhai Z, Shu HB. Identification of downstream genes up-regulated by the tumor necrosis factor family member TALL-1. J Leukoc Biol. 2002. 72:410–416.

76. Kanters E, Pasparakis M, Gijbels MJ, Vergouwe MN, Partouns-Hendriks I, Fijneman RJ, Clausen BE, Forster I, Kockx MM, Rajewsky K, Kraal G, Hofker MH, de Winther MP. Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2003. 112:1176 –1185.

77. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, Soubrier F, Esposito B, Duez H, Fievet C, Staels B, Duverger N, Scherman D, Tedgui A. Protective role of interleukin-10 in atherosclerosis. Circ Res. 1999. 85:e17–e24.

78. Von Der Thusen JH, Kuiper J, Fekkes ML, De Vos P, Van Berkel TJ, Biessen EA. Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/- mice. Faseb J. 2001. 15:2730–2732.

79. Caligiuri G, Rudling M, Ollivier V, Jacob MP, Michel JB, Hansson GK, Nicoletti A. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol Med. 2003. 9:10–17.

80. Elhage R, Clamens S, Besnard S, Mallat Z, Tedgui A, Arnal J, Maret A, Bayard F. Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17beta-estradiol in apolipoprotein E-deficient mice. Atherosclerosis. 2001. 156:315–320.

81. Tabas I. Apoptosis and plaque destabilization in atherosclerosis: the role of macrophage apoptosis induced by cholesterol. Cell Death Differ. 2004. 11:suppl 1. S12–S16.

82. Autieri MV, Yue TL, Ferstein GZ, Ohlstein E. Antisense oligonucleotides to the p65 subunit of NF-kB inhibit human vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries. Biochem Biophys Res Commun. 1995. 213:827–836.

83. Hoshi S, Goto M, Koyama N, Nomoto K, Tanaka H. Regulation of vascular smooth muscle cell proliferation by nuclear factor-kappaB and its inhibitor, I-kappaB. J Biol Chem. 2000. 275:883–889.

84. Selzman CH, Shames BD, McIntyre RC Jr, Banerjee A, Harken AH. The NFkappaB inhibitory peptide, IkappaBalpha, prevents human vascular smooth muscle proliferation. Ann Thorac Surg. 1999. 67:1227–1231.

85. Zuckerbraun BS, McCloskey CA, Mahidhara RS, Kim PK, Taylor BS, Tzeng E. Overexpression of mutated IkappaBalpha inhibits vascular smooth muscle cell proliferation andintimal hyperplasia formation. J Vasc Surg. 2003. 38:812–819.

86. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002. 23:599–622.

87. Jeong IK, Chae MK, Choi MH, Kim S, Lee MS, Yoo HJ. Inhibition of NF-KB activity protects proliferation and PAI-1 expression induced by high glucose in vascular smooth muscle cells. Diabetologia. 2004. 47:suppl 1. A434.

88. de Winther MP, Kanters E, Kraal G, Hofker MH. Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol. 2005. 25:904–914.

89. Rohl M, Pasparakis M, Baudler S, Baumgartl J, Gautam D, Huth M, De Lorenzi R, Krone W, Rajewsky K, Bruning JC. Conditional disruption of IkappaB kinase 2 fails to prevent obesity-induced insulin resistance. J Clin Invest. 2004. 113:474–481.